Basit öğe kaydını göster

dc.contributor.authorYilmaz, Mustafa
dc.contributor.authorAtar, Ilyas
dc.contributor.authorHasirci, Senem
dc.contributor.authorAkyol, Kadirhan
dc.contributor.authorTekin, Abdullah
dc.contributor.authorKaracaglar, Emir
dc.contributor.authorCiftci, Orcun
dc.contributor.authorMuderrisoglu, Haldun
dc.date.accessioned2019-06-13T22:36:57Z
dc.date.available2019-06-13T22:36:57Z
dc.date.issued2017
dc.identifier.issn2149-2263
dc.identifier.urihttp://www.journalagent.com/anatoljcardiol/pdfs/AJC-91297-ORIGINAL_INVESTIGATION-YILMAZ.pdf
dc.identifier.urihttp://hdl.handle.net/11727/3533
dc.description.abstractOBJECTIVE: Atherosclerotic cardiovascular disease is a major global cause of death. The common approach in primary prevention of cardiovascular disease is to identify patients at high risk for cardiovascular disease. This article analyzes and compares the application of 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline and the 2011 European Society of Cardiology (ESC) guideline for the management of dyslipidemias for primary prevention in Turkish population. METHODS: The study included 833 patients (482 women and 351 men). Risk scores were calculated according to both guidelines and indications for statin treatment were determined according to sex and age group. Variables are presented as mean +/- SD or median with interquartile range for continuous data and as proportions for categorical data. Variables were analyzed by unpaired t-test, Mann-Whitney U test, chi-square or Fischer's exact test as appropriate. RESULTS: The ACC/AHA would suggest statin treatment in 415 patients out of 833 (49.5%), while ESC would recommend statin for 193 patients out of 833 (23.1%)(p<0.001). Statins would be recommended for 40.4% of women and 62.6% of men for primary prevention by the ACC/AHA, while this figure was 12% for women and 38.4% for men according to the ESC guideline (p<0.001 for both). CONCLUSION: When compared to the ESC guideline, the ACC/AHA guideline suggests augmented statin treatment for primary prevention in Turkish populationen_US
dc.language.isoengen_US
dc.relation.isversionof10.14744/AnatolJCardiol.2016.6965en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGuidelinesen_US
dc.subjectPreventive cardiologyen_US
dc.subjectStatinsen_US
dc.subjectDyslipidemiasen_US
dc.titleComparison of application of 2013 ACC/AHA guideline and 2011 European Society of Cardiology guideline for the management of dyslipidemias for primary prevention in a Turkish cohorten_US
dc.typearticleen_US
dc.relation.journalANATOLIAN JOURNAL OF CARDIOLOGYen_US
dc.identifier.volume17en_US
dc.identifier.issue2en_US
dc.identifier.startpage92en_US
dc.identifier.endpage96en_US
dc.identifier.wos000396901400004en_US
dc.identifier.scopus2-s2.0-85015306535en_US
dc.contributor.pubmedID27684519en_US
dc.contributor.orcID0000-0002-9635-6313en_US
dc.contributor.orcID0000-0002-2538-1642en_US
dc.contributor.orcID0000-0001-8926-9142en_US
dc.contributor.orcID0000-0002-8342-679Xen_US
dc.contributor.orcID0000-0002-5658-870Xen_US
dc.contributor.orcID0000-0002-2557-9579en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDAAG-8233-2020en_US
dc.contributor.researcherIDABI-6723-2020en_US
dc.contributor.researcherIDW-5233-2018en_US
dc.contributor.researcherIDAAK-7805-2021en_US
dc.contributor.researcherIDABD-7304-2021en_US
dc.contributor.researcherIDS-6973-2016en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster